Degarelix: a guide to its use in advanced prostate cancer
Drugs & Therapy Perspectives, 04/05/2012
Lyseng-Williamson KA - Degarelix, a gonadotropin–releasing hormone (GnRH) receptor antagonist, is indicated as an androgen–deprivation therapy in men with advanced hormone–dependent prostate cancer. It effectively induces and maintains suppression of serum testosterone to castration levels and has an acceptable tolerability profile. Relative to leuprolide, degarelix is associated with more rapid induction of testosterone and prostate–specific antigen (PSA) suppression without the testosterone surges associated with GnRH receptor agonists, and a potentially lower risk of the combined endpoint of PSA progression and death.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.